Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Graft-vs.-Host Disease

Graft-vs.-Host Disease

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Graft-vs.-Host Disease

29 trials tracked for Graft-vs.-Host Disease: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 35 citations.

29Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 2 Phase 2 22 Phase 1 1 Other / NA 3
  1. Phase 3 A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) Completed · 35 cited
  2. Phase 4 A Study Comparing the Withdrawal of Steroids or Tacrolimus in Kidney Transplant Recipients Completed
  3. Phase 3 Study Evaluating Sirolimus in Kidney Transplant Recipients Completed
  4. Phase 2 Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Completed
  5. Phase 2 Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease Completed
  6. Phase 2 Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Completed
Show 23 more trials
  1. Phase 2 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant Completed
  2. Phase 2 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Completed
  3. Phase 2 A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease Completed
  4. Phase 2 Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant Completed
  5. Phase 2 A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease Completed
  6. Phase 2 CC-4047 (Pomalidomide) for Graft vs. Host Disease Completed
  7. Phase 2 Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Completed
  8. Phase 2 Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation Completed
  9. Phase 2 Pomalidomide for Chronic Graft-versus-Host Disease Completed
  10. Phase 2 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome Completed
  11. Phase 2 A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression Completed
  12. Phase 2 RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation Completed
  13. Phase 2 Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD Completed
  14. Phase 2 Abatacept as GVHD Prophylaxis Phase 2 Completed
  15. Phase 2 Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease Completed
  16. Phase 2 Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation Completed
  17. Phase 2 Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation Completed
  18. Phase 2 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye Completed
  19. Phase 2 Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant Completed
  20. Phase 1 Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation Completed
  21. N/A Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Completed
  22. N/A Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease Completed
  23. N/A A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease Completed

Showing the 29 most-cited and recently-updated of 29 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Graft-vs.-Host Disease: what the trials found

Chronic Graft-Versus-Host Disease (cGVHD) management includes several established interventions. Ibrutinib demonstrated a cGVHD response rate reaching up to 52.6% at various time points, with 52.6% of participants showing an overall improvement in Lee cGVHD symptom scores 3. Sirolimus has been evaluated in multiple trials for the management of this condition [4, 20]. Additionally, Tacrolimus was evaluated regarding biopsy-confirmed acute rejection at 12 months, where results showed no statistically significant difference between groups (p=1.0) 2.

Recent results — preliminary, needs further review

  • * Belimumab is currently being investigated in a Phase 1 trial for Graft-vs.-Host Disease 1.

For the clinician treating this condition

  • Ibrutinib has shown clinical activity in cGVHD with over half of patients achieving improved Lee symptom scores 3.
  • Sirolimus and Tacrolimus are established interventions within the treatment landscape, though Tacrolimus data specifically focused on acute rejection rates [2, 4, 20].

AI synthesis of 3 cited trials, updated Aug 22, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.